This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 28/8/1484    most recent ATVBAHA.108.168971v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Herrera-Galeano, J. E. Articles by Becker, L. C. PubMed PubMed Citation Articles by Herrera-Galeano, J. E. Articles by Becker, L. C. Pubmed/NCBI databases Gene GEO Profiles HomoloGene Nucleotide Protein UniGene

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1484.)
© 2008 American Heart Association, Inc.

Cell Biology/Signaling

A Novel Variant in the Platelet Endothelial Aggregation Receptor-1 Gene Is Associated With Increased Platelet Aggregability

J. Enrique Herrera-Galeano; Diane M. Becker; Alexander F. Wilson; Lisa R. Yanek; Paul Bray; Dhananjay Vaidya; Nauder Faraday; Lewis C. Becker

From the Departments of Medicine and Anesthesiology (J.E.H.-G., D.M.B., L.R.Y., D.V., L.C.B.) and Critical Care Medicine (N.F.), Johns Hopkins University School of Medicine, Baltimore, Md; Inherited Disease Research Branch (A.F.W.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Md; and the Department of Medicine (P.B.), Thomas Jefferson University Hospital, Philadelphia, Pa.

Correspondence to Lewis C. Becker, MD, Halsted 500, Johns Hopkins Hospital, 600 N Wolfe Street, Baltimore, Maryland 21287. E-mail lbecker{at}mail.jhmi.edu

Abstract

Objective— Platelet endothelial aggregation receptor-1 (PEAR1) is a recently identified platelet transmembrane protein that becomes activated by platelet contact. We looked for novel genetic variants in PEAR1 and studied their association with agonist-induced native platelet aggregation and with the inhibitory effect of aspirin on platelets.

Methods and Results— We genotyped PEAR1 for 10 single nucleotide polymorphisms (SNPs), selected for optimal gene coverage at a density of 4 kb, in 1486 apparently healthy individuals from two generations of families with premature CAD. Subjects had a mean age of 45 years; 62% were white and 38% black. Platelet aggregation to collagen, epinephrine, and ADP was measured in platelet rich plasma, at baseline and after 2 weeks of aspirin (ASA, 81 mg/d), and genotype-phenotype associations were examined separately by ethnicity using multivariable generalized linear models adjusted for covariates. The C allele of SNP rs2768759 [A/C], located in the promoter region of the gene, was common in whites and uncommon in blacks (allele frequency 70.2% versus 17.7%). The C allele was generally associated in both ethnic groups with increased aggregation of native platelets to each agonist. After ASA, the associations were stronger and more consistent and remained significant when post-ASA aggregation was adjusted for baseline aggregation, consistent with a relationship between the C allele and reduced platelet responsiveness to ASA. The PEAR1 SNP explained up to 6.9% of the locus specific genetic variance in blacks and up to 2.5% of the genetic variance in whites after ASA.

Conclusion— PEAR1 appears to play an important role in agonist-induced platelet aggregation and in the response to ASA in both whites and blacks.

This study examined the association between genetic variants in platelet endothelial aggregation receptor-1 (PEAR1) and platelet function in 1486 healthy individuals from families with premature CAD. The C allele of SNP rs2768759, in the promoter region, was common in whites and uncommon in blacks but was associated with greater platelet aggregation to collagen, epinephrine, and ADP in native platelets and after aspirin in both ethnic groups. PEAR1 appears to play an important role in platelet function.

Key Words: platelets • genetics • aspirin • family study